Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-01-04 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Foreign Filer Report
2021-01-04 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange's news service) on January 4, 2021. The content explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights as of December 31, 2020. This type of regulatory disclosure regarding the total issued share capital and voting rights is a standard regulatory announcement. Since there is no specific category for 'Voting Rights Notification' among the provided codes, and it is a general regulatory announcement distributed via RNS, the most appropriate classification is the general regulatory filing fallback, RNS, although it is closely related to capital structure. However, given the specific nature of the content (voting rights denominator), it is a mandatory regulatory disclosure. If 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is interpreted broadly to include the denominator for voting rights, it could fit. But DVA is defined as 'Official results from shareholder votes'. This document is a routine disclosure of the total voting rights count, which is often categorized under general regulatory filings when specific codes are absent. Given the context of RNS distribution and the nature of the disclosure (Transparency Directive compliance), RNS is the safest general regulatory fit, but let's re-evaluate against the definitions. The document is not an AGM result (DVA), nor a capital change (SHA/CAP). It is a mandatory regulatory disclosure. RNS is the best fit for general regulatory announcements not covered elsewhere.
2021-01-04 English
ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED
Foreign Filer Report
2021-01-04 English
Atacand divestment in over 70 countries completed
M&A Activity Classification · 99% confidence The document is very short (3756 characters) and contains the header 'RNS Number : 3967K' and concludes with information about RNS, the news service of the London Stock Exchange. The content announces the completion of a divestment and provides financial details related to that transaction. This structure strongly suggests a regulatory news service announcement rather than a comprehensive report (like 10-K or IR). Since it is a general regulatory announcement distributed via RNS and doesn't fit specific categories like Capital Change (SHA) or M&A (TAR), the most appropriate classification is the general Regulatory Filings category (RNS).
2021-01-04 English
ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK
Foreign Filer Report
2020-12-30 English
AstraZeneca’s COVID-19 vaccine authorised in UK
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 1114K' and contains a date stamp typical of regulatory news services. The content announces the emergency supply authorisation of AstraZeneca's COVID-19 vaccine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This is a time-sensitive, material announcement released via RNS (Regulatory News Service). Since it is a general regulatory announcement that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), and it is clearly distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (9075 chars), but its nature is that of a formal regulatory disclosure rather than a comprehensive financial report.
2020-12-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.